ArticleProbiotics and antimicrobial proteins2026
Postbiotic Potential of Newly Isolated Riboflavin-Overproducing Lactiplantibacillus plantarum Strains.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exploring the Diversity and Applications of Lactic Acid Bacteria from Tunisian Traditional Fermented Foods.Microorganisms · 2026Review
- Intratumoral microbiome signatures in a North Central Indian colorectal cancer cohort: identification of novel prognostic biomarkers and functional pathways.Scientific reports · 2026Article
- Postbiotics of Marine Origin and Their Therapeutic Application.Marine drugs · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactic acid bacteria (LAB) are food-grade microorganisms able to produce and release bioactive compounds of interest to human health. Some LAB strains can synthesize vitamin B2, i.e., riboflavin, a micronutrient essential for cellular metabolism. In this work, six Lactiplantibacillus plantarum isolated from fruits of the Mediterranean area were exposed to the selective pressure of roseoflavin in order to select spontaneous riboflavin-overproducing phenotypes. The best strains, as determined by the level of riboflavin produced, were characterized for some basic probiotic features, including antibacterial activity, production of organic acids, antibiotic resistance, and survival under digestive stresses using an in vitro gut model. The strain L. plantarum Lp 187_B2, which produced the highest riboflavin level (6 mg/L), exhibited good resistance to gastro-intestinal stress and a relevant capacity to antagonize undesired bacteria, was selected for additional investigations to assess its capacity to protect intestinal homeostasis. When used as a postbiotic, Lp 187_B2 significantly increased trans-epithelial electrical resistance (TEER) in Caco-2 cell monolayers, an in vitro model of the intestinal barrier. Moreover, in a Caco-2/THP-1 co-culture system, mimicking the inflamed bowel, Lp 187_B2 postbiotics significantly inhibited the release of TNF-α by macrophages, thus pointing to gut-barrier strengthening and potential anti-inflammatory properties. Though a validation in vivo is required, our preliminary results indicate that L. plantarum Lp 187_B2 could be successfully applied as both probiotic and postbiotic formulations for improving human health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.